Viking Q3 net loss $22.5M; cash $376M; obesity trial fully enrolled

Viking Therapeutics, Inc.

2023-Q3 EPS reported -$0.66

Net loss of $22.5M ($0.23/sh) vs $15.8M in Q3 2022; R&D expenses $18.4M, up from $12.0M.
Cash & equivalents $376M at Sept 30, 2023, vs $155.5M at Dec 31, 2022 (includes $287.5M public offering).
Phase 2 VENTURE trial of VK2735 (GLP-1/GIP agonist) for obesity fully enrolled (n=176); results expected 1H24.
Phase 1 oral VK2735 study ongoing; data expected 1Q24. Phase 2b VOYAGE (VK2809 for NASH) histology results expected 1H24.
Phase 1b VK0214 for X-ALD enrolling; enrollment completion expected 4Q23.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.